Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients (NCT05441696) | Clinical Trial Compass
By InvitationNot Applicable
Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients
United States65 participantsStarted 2022-06-01
Plain-language summary
Track changes in non-invasive central venous pressure across hospital stay and relationship with readmission
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Arm circumference of 23 cm to 55 cm
* Subject admitted to the hospital with acute exacerbation of heart failure, with either reduced or preserved ejection fraction
* Subject is at risk for readmission (NYHA Functional Classification 2-3)
* Subject is able to understand the risks and potential benefits of participating in the study and is willing to provide written, informed consent
* ezCVP indicator is high (CVPNI is over 9 mmHg) at admission
* Subject is willing and able to comply with protocol procedures
* Subject tested negative for COVID test after admission to the hospital
Exclusion Criteria:
* Finger and upper arm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor and/or blood pressure cuff
* Pregnant (self-reported)
* Upper extremity DVT (currently being treated)
* Severe skin disease involving the upper arm(s)
* Study investigator may exclude patients based on clinical judgement
What they're measuring
1
Evaluate the difference between non-invasive CVP measurement at admission and at discharge
Timeframe: 7 days
2
Evaluate the difference between non-invasive CVP measurement in right and left arms